Not planned for U.S. and UK Media
Berlin, June 5, 2023 — Bayer AG is signing up with forces with Acuitas Therapeutics, Inc., a biotechnology business focusing on the advancement of lipid nanoparticle (LNP) shipment systems for molecular rehabs. Acuitas’ LNP innovation will support Bayer’s in vivo gene modifying and protein replacement programs by particularly providing RNA payloads to the preferred target organ, the liver.
LNPs are spheric drug shipment bodies which can be geared up with restorative payloads for intracellular shipment. Acuitas’ exclusive LNP innovation is utilized in several vaccines and rehabs in medical advancement and was likewise utilized in a few of the COVID-19 vaccines that were authorized and administered to individuals in 180 nations. This shipment innovation secures the messenger RNA (mRNA) payload after administration permitting it to be securely and successfully provided into cells. In addition to mRNA, Acuitas LNP can be utilized to provide a variety of various nucleic acid therapies consisting of little interfering RNA (siRNA), antisense oligonucleotides and DNA.
“Complementing internal know-how with external partnership continues to be a top priority in locations of high unmet medical requirement where inadequate, or no treatment choices are presently offered,” stated Friedemann Janus, acting Head of Business Development and Licensing/Open Innovation, Pharmaceuticals Division, Bayer. “Accessing advanced LNP innovation through this partnership will include momentum to our gene modifying efforts for the advantage of clients.”
“Developing treatments at scale is basic to offer development developments to clients who have no time at all to wait,” stated Jost Reinhardt, Head of Cell and Gene Therapy, Pharmaceuticals Division, Bayer. “Adding Acuitas’ clinically-validated and scalable LNP innovation to our genomic medication tool kit is another crucial action to advance our management in the field of cell and gene treatments.”
“We are happy t